Dr. Reddy’s Laboratories launches migraine management wearable Nerivio in Germany
In an exciting development for migraine sufferers, Dr. Reddy’s Laboratories Ltd., a leader in the global pharmaceutical industry, has announced the launch of its groundbreaking, drug-free, non-invasive migraine management device, Nerivio, in Germany. This move, facilitated through its step-down subsidiary betapharm, signifies Dr. Reddy’s Laboratories’ foray into the realm of digital therapeutics in Europe, marking a significant milestone in the company’s expansion and innovation in healthcare solutions.
Nerivio: A New Horizon in Migraine Management
Nerivio, a wearable device approved by the United States Food and Drug Administration (USFDA) and CE-mark certified in Europe, represents a novel approach in the treatment of migraine. Designed as a prescription-based non-invasive device for the acute and prophylactic treatment of migraine in adults and adolescents aged 12 years and above, Nerivio has shown promising results in clinical trials, benefiting over 45,000 patients worldwide. The device operates on the Remote Electrical Neuromodulation (REN) mechanism, stimulating nerve endings to activate conditioned pain modulation, thus initiating a natural pain-relieving process.
Expanding Reach: From Europe to Africa
Dr. Reddy’s unveiled Nerivio at several prestigious medical gatherings, including the DGN Congress organized by the German Association of Neurology and the European Headache Congress. The company plans to further showcase and launch Nerivio at the Neurological Association of South Africa’s annual congress, with notable attendance from Dr. Stewart Tepper, a prominent figure in neurology. Additionally, presentations are scheduled at the upcoming International Headache Society 2024 iHEAD meeting in Berlin, with launches in Spain and the UK to follow, broadening the device’s accessibility to migraine sufferers across continents.
A Comprehensive Support System: M-Free Program
In India, Nerivio’s launch was accompanied by the M-Free program, a unique patient support initiative aimed at enhancing the patient journey through services like onboarding, counseling, device demonstrations, doorstep delivery, and more. The program emphasizes lifestyle modifications for managing migraine, offering value-added services such as nutritionist consultations and yoga sessions, illustrating Dr. Reddy’s commitment to holistic health solutions.
Migraine: A Global Health Challenge
Migraine remains a prevalent global health issue, affecting approximately 30% of adults with frequent episodes monthly. The condition poses a greater risk to women, with a significant number suffering from migraines worldwide. Nerivio’s introduction into various markets addresses the unmet clinical needs of these patients, offering a non-pharmacological option that has the potential to lessen the dependency on medications.
According to M.V. Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, the launch of Nerivio is a step forward in addressing the clinical needs of migraine sufferers, offering a technology-driven solution that has shown efficacy in relieving migraine symptoms. The feedback from patients and healthcare professionals in the markets where Nerivio has been introduced has been positive, underlining the device’s potential in migraine management.
Dr. Reddy’s Laboratories Ltd.’s introduction of Nerivio in Germany is a landmark event in the field of digital therapeutics and migraine management. By offering a non-invasive, drug-free option, the company is paving the way for innovative treatments that align with patients’ needs for effective and manageable migraine solutions. As Nerivio continues to be rolled out in new markets, its potential to transform migraine care on a global scale is increasingly evident.